Table 3.
SNPs related to Efficacy in terms of Survival.
| Gene | SNP | Results | Involved Candidate Drug * | ||
|---|---|---|---|---|---|
| Genotype | HR | Association | |||
| OS | |||||
| MTHFR | rs1801133 | TC | 0.65 | ↑ OS | Platinum-compounds Cyclophosphamide |
| Unidentified | rs7186128 | GG | 0.89 | ↑ OS | |
| VDR | rs1544410 | GA | 1.39 | ↓ OS | Etoposide |
| EFS | |||||
| ABCB1 | rs2032582 | GA | 0.48 | ↑ EFS | Cyclophosphamide |
| SOD2 | rs4880 | TC | 0.72 | ↑ EFS | |
| NR1I2 | rs3814058 | TT | 0.62 | ↑ EFS | Etoposide |
| ABCC1 | rs45511401 | GT | 1.79 | ↓ EFS | |
| VDR | rs1544410 | GA | 1.75 | ↓ EFS | |
| Unidentified | rs6539870 | GG | 1.61 | ↓ EFS | |
EFS: event-free survival; HR: Hazard Ratio; OS: overall survival; SNP: Single Nucleotide Polymorphism. * According to literature and PharmGKB. N = 95 patients. ↑ means “increase” and ↓ “decrease”.